πŸ”¬

Optogenetics

1
Open Unknowns
0
Cross-Domain Bridges
1
Active Hypotheses

Open Unknowns (1)

Unknown What are the barriers to scaling optogenetic therapies from proof-of-concept (retinitis pigmentosa) to broader neurological conditions (Parkinson's, epilepsy, depression) ΓÇâ specifically the challenges of viral vector delivery, light penetration through tissue, and long-term immune tolerance? u-optogenetics-human-therapeutic-scale-delivery

Active Hypotheses

Hypothesis Optogenetic vision restoration in retinitis pigmentosa will scale from detection of motion and high-contrast objects (demonstrated 2021) to recognition of faces and reading text within 5 years, as improved opsins (faster kinetics, red-shifted sensitivity), higher density transduction, and adaptive goggles are combined. high

Know something about Optogenetics? Contribute an unknown or hypothesis β†’

Generated 2026-05-10 Β· USDR Dashboard